A study from the University of California, Los Angeles; California Institute of Technology, Pasadena; Medical Research Council, National Institute for Medical Research, London has reported that “Transcriptomics identified a critical role for Th2 cell-intrinsic miR-155 in mediating allergy and antihelminthimmunity.”
This study was published in the July 14, 2014 Proc Natl Acad Sci U S A [I.F >10] by the 1975 Nobel prize winner for Physiology/Medicine, Prof. David Baltimore and others from the University of California, Los Angeles; California Institute of Technology, Pasadena; Medical Research Council, National Institute for Medical Research, London.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Insights into the treatment of Th2-mediated inflammation and allergic diseases: Nitric oxide alleviates Th2-mediated inflammation and Allergy via up regulation of its target gene. This study suggests that TGFβ, by suppressing the expression of its target gene, it could promote antihelminthimmunity. Together, this study suggests that pharmacological formulations encompassing “Nitric oxide activators” can be used to treat inflammation and allergic diseases.
Idea Proposed/Formulated by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Courtesy: When you cite drop us a line at info@genomediscovery.org
Citation: Boominathan, Insights into the treatment of Th2-mediated inflammation and allergic diseases: Nitric oxide alleviates Th2-mediated inflammation and Allergy via up regulation of its target gene, 7/October/2014, 7.53 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
*Research cooperation